期刊
CURRENT PHARMACEUTICAL DESIGN
卷 27, 期 40, 页码 4179-4185出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612827666210715155809
关键词
Berberine; transcription; ubiquitination degradation; X receptor (PXR); RT-PCR
资金
- Jiangsu Pharmaceutical Association-Hengrui Pharmaceutical Services Special Scientific Research Funding Project
- Nantong Science and Technology Plan Project [JCZ20169, JC2019146]
- Heilongjiang Natural Science Foundation [YQ2019H022]
The study revealed that berberine inhibits the transcription of CYP3A4 gene by downregulating nuclear receptor PXR, and accelerates the degradation of CYP3A4 protein via polyubiquitination pathway. These findings provide insights into the mechanisms of drug-drug interactions involving berberine.
Background: Berberine (BBR) is an isoquinoline alkaloid extracted from the Chinese medicine, exerting a variety of pharmacological effects. BBR is partially metabolized by cytochrome 3A4 (CYP3A4) in vivo. Some reports indicated that BBR could inhibit the activity of CYP3A4. However, the underlying mechanisms are not completely understood. CYP3A4 is reported to be transcriptionally regulated by two nuclear re-ceptors, nuclear transcription X receptor (PXR) and constitutive androstane receptor (CAR), and degraded via the ubiquitin-proteasome system. Hence, we tried to explore the mechanisms of CYP3A4 inhibition on both transcriptive and protein levels. Methods: Western Blot, RT-PCR and Co-immunoprecipitation were used to perform the experiments. Results: Our results showed that BBR inhibited the transcription of CYP3A4 gene by downregulating PXR. In addition, BBR accelerated the degradation of CYP3A4 protein via polyubiquitination pathway. Conclusion: These findings may lead to the determination of novel drug-drug interactions with BBR, and con-tribute to future clinical application of BBR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据